TGF beta and IL13 in schistosomiasis mansoni associated pulmonary arterial hypertension; a descriptive study with comparative groups

BMC Infectious Diseases

Milena Oliveira Almeida²  Alessandra Brainer Mertens²  Izolda Moura Fernandes³  Clara de Almeida Pereira¹  Luiz Arthur Calheiros Leite⁵  Carlos Antonio da Mota Silveira²  Angela Pontes Bandeira²  Ana Lucia Coutinho Domingues³  Silvia Maria Lucena Montenegro⁶  Rita de Cassia dos Santos Ferreira⁴ 

[1] Biological Sciences Center, Universidade Federal de Pernambuco, Recife, Brazil;Reference Center of Pulmonary Hypertension, Pronto Socorro Cardiológico de Pernambuco, Universidade de Pernambuco, Recife, Brazil;Departament of Clinical Medicine, Health Sciences Center, Universidade Federal de Pernambuco, Recife, Brazil;Department of Tropical Medicine, Health Sciences Center, Universidade Federal de Pernambuco, Recife, Brazil;Department of Biochemistry, Health Sciences Center, Universidade Federal de Pernambuco, Recife, Brazil;Department of Immunology, Centro de Pesquisas Aggeu Magalhães - Fundação Oswaldo Cruz, Recife, Brazil

关键词: Interleukin 13;    Transforming growth factor-beta;    Pulmonary hypertension;    Schistosomiasis;   

Others  :  1127726
DOI  :  10.1186/1471-2334-14-282

 received in 2013-07-08, accepted in 2014-05-14,  发布年份 2014

【 摘 要 】

Background

It is suggested that interleukin (IL)-13 and transforming growth factor (TGF)-beta play a role in the pulmonary vascular changes found in animal models of schistosomiasis. The aim of this study was to assess and compare the serum levels of total TGF-beta and IL-13 of patients with schistosomiasis with pulmonary arterial hypertension (PAH) and patients with schistosomiasis without PAH.

Methods

34 patients from the schistosomiasis outpatient clinic of the Hospital das Clinicas, Recife, Pernambuco, Brazil, without PAH assessed by echocardiography and 34 patients from the Reference Centre of Pulmonary Hypertension of Pronto Socorro Cardiológico de Pernambuco, Recife, Brazil with PAH, confirmed by right heart catheterization, were enrolled on the study. Both groups presented with schistosomal periportal fibrosis after abdominal ultrasound. Serum levels of TGF-beta1 and IL-13 were determined by ELISA. Student t test to independent samples, Mann-Whitney test to nonparametric variables, Pearson correlation test for correlation analyses and Fisher Chi-squared test to compare categorical analyses were used.

Results

The median value of TGF-beta1 was significantly higher in patients with PAH (22496.9 pg/ml, interquartile range [IR] 15936.7 – 32087.8) than in patients without PAH (13629.9 pg/ml, IR: 10192.2- 22193.8) (p = 0.006). There was no difference in the median value of IL-13 in the group with Sch-PAH compared to patients without Sch-PAH (p > 0.05).

Conclusion

Our results suggest that TGF-beta possibly plays a role in the pathogenesis of schistosomiasis-associated PAH.

【 授权许可】

   
2014 Ferreira et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G: Guidelines for diagnosis and treatment of pulmonary hypertension. The Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Respir J 2009, 34:1219-1263.
• [2]Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Sanchez MAG, Kumar RK, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013, 62(25 Suppl):D34-D41.
• [3]Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM: Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 2010, 137:20S-29S.
• [4]Chitsulo L, Engels D, Montresor A, Savioloi L: The global status of schistosomiasis and its control. Acta Trop 2000, 77(1):41-51.
• [5]Ross AG, Bartley PB, Sleigh AC, Olds GR, Li Y, Williams GM, McManus DP: Schistosomiasis. N Engl J Med 2002, 346:1212-1220.
• [6]Ward TJC, Fenwick A, Butrous G: The prevalence of pulmonary hypertension in schistosomiais: a systematic review. PVRI Rev 2011, 3(1):12-21.
• [7]Ferreira RC, Domingues AL, Bandeira AP, Markman-Filho B, Albuquerque-Filho ES, de Correia Araújo AC, Batista LJB, Markman M, Campelo ARL: Prevalence of pulmonary hypertension in patients with schistosomal liver fibrosis. Ann Trop Med Parasitol 2009, 103:129-143.
• [8]Lapa M, Dias B, Jardim C, Fernandes CJ, Dourado PM, Figueiredo M, Farias A, Tsutsui J, Terra-Filho M, Humbert M, Souza R: Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009, 119:1518-1523.
• [9]Gryseels B, Polman K, Clerinx J, Kestens L: Human schistosomiasis. Lancet 2006, 368:1106-1118.
• [10]Abath FGC, Morais CNL, Montenegro CEL, Wynn TH, Montenegro SML: Immunopathogenic mechanisms in schistosomiasis: what can be learnt from human studies? Trends Parasitol 2006, 22(2):85-91.
• [11]Morais CNL, Souza JR, Melo WG, Aroucha ML, Miranda P, Domingues ALC, Abath FGC, Montenegro SML: Cytokine profile associated with chronic and acute human schistosomiasis mansoni. Mem Inst Oswaldo Cruz 2008, 103(6):561-568.
• [12]Wilson MS, Mentink-Kane MM, Pesce JT, Ramalingam TR, Thompson R, Wynn TA: Immunopathology of schistosomiasis. Immunol Cell Biol 2007, 85(2):148-154.
• [13]Caldas RC, Campi-Azevedo AC, Oliveira LFA, Silveira AMS, Oliveira RC, Gazzinelli G: Human schistosomiasis mansoni: immune responses during acute and chronic phases of the infection. Acta Trop 2008, 108(2–3):109-117.
• [14]Yu L, Sun X, Yang F, Yang J, Shen J, Wu Z: Inflammatory cytokines IFN-Ƴ, IL-4, IL-13 and TNF-α alterations in schistosomiasis: a meta-analysis. Parasitol Res 2012, 110(4):1547-1552.
• [15]Warren KS: Hepatosplenic schistosomiasis: a great neglected disease of the liver. Gut 1978, 19:572-577.
• [16]Domingues ALC, Ferraz AAB: Doença Hepática Esquistossomótica. In Aparelho Digestivo: Clínica e Cirurgia. Edited by Coelho J. São Paulo: Editora Atheneu; 2012:1559-1575.
• [17]Strauss E: Hepatosplenic schistosomiasis: a model for the study of portal hypertension. Ann Hepatol 2002, 1(1):6-11.
• [18]Morris W, Knauer CM: Cardiopulmonary manifestations of schistosomiasis. Semin Respir Infect 1997, 12(2):159-170.
• [19]Graham BB, Chabon J, Bandeira A, Espinheira L, Butrous G, Tuder RM: Significant intrapulmonary schistosoma egg antigens are not present in schistosomiasis-associated pulmonary hypertension. Pulm Circ 2011, 1(4):456-461.
• [20]Tuder RM: Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009, 30:376-385.
• [21]Nicod LP: The endothelium and genetics in pulmonary arterial hypertension. Swiiss Med Wkly 2007, 137:437-442.
• [22]Newman JH, Phillips JA 3rd, Loyd JE: Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann Intern Med 2008, 148:278-283.
• [23]Goumans MJ, Liu Z, ten Dijke P: TGF-β signaling in vascular biology and disfunction. Cell Res 2009, 19:116-127.
• [24]Price LC, Wort SJ, Perros F, Dormüller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M: Inflammation in pulmonary arterial hypertension. Chest 2012, 141(1):210-221.
• [25]Graham BB, Mentink-Kane MM, El-Haddad H, Purnell S, Zhang L, Zaiman A, Redente EF, Riches DWH, Hassoun PM, Bandeira AG, Champion HC, Butrous G, Wynn TA, Tuder RM: Schistosomiaisis-induced experimental pulmonary hypertension. role of interleukin-13 signaling. Amer J Pathol 2010, 177(3):1549-1561.
• [26]Crosby A, Jones FM, Southwood M, Stewart S, Schermuly R, Butrous G, Dunne DW, Morrel NW: Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med 2010, 181:279-288.
• [27]Graham BB, Chabon J, Gebreab L, Poole J, Debella E, Davis L, Tanaka T, Sanders L, Dropcho N, Bandeira A, Vandivier RW, Champion HC, Butrous G, Wang X, Wynn TA, Tuder RM: Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni. Circulation 2013, 128:1354-1364.
• [28]Walsh K, Alexander G: Alcoholic liver disease. Postgrad Med J 2000, 76:280-286.
• [29]Richter J, Domingues ALC, Barata CH, Prata AR, Lambertucci JR: Report of the second satellite symposium on ultrasound in schistosomiasis. Mem Inst Oswaldo Cruz 2001, 96(Suppl):151-156.
• [30]Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ: Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18(12):1440-1463.
• [31]Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S: Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12):40S-47S.
• [32]Gupta H, Ghimire G, Naeije R: The value of tools to assess pulmonary arterial hypertension. Eur Respir Rev 2011, 20(122):222-235.
• [33]Morrel NW, Yang X, Upton PD, Jourdan KB, Morgan N, Sheares KK, Trembath RC: Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic protein. Circulation 2001, 104:790-795.
• [34]Selimovic N, Bergh CH, Anderson B, Sakiniene E, Carlsten H, Rundqvist B: Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009, 34(3):662-668.
• [35]Zaiman AL, Podowski M, Medicherla S, Gordy K, Xu F, Zhen L, Shimoda LA, Neptune E, Higgins L, Murphy A, Chakravarty S, Protter A, Sehgal PB, Champion HC, Tuder RM: Role of TGF-β-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 2008, 177:896-905.
• [36]Long L, Crosby A, Yang X, Southwood M, Upton PD, Kim DK, Morrell NW: Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 2009, 119:566-576.
• [37]Megalou AJ, Glava C, Oikonomidis DL, Vilatei A, Agelaki MG, Baltogiannis GG, Papalois A, Vlahos AP, Kolettis TM: Transforming growth factor-beta inhibition attenuates pulmonary arterial hypertension in rats. Int J Clin Exp Med 2011, 3:332-340.
• [38]Star GP, Giovinazzo M, Langleben D: Effects of bone morphogenic proteins and tranforming growth factor-beta on in-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascul Pharmacol 2009, 50(1-2):45-50.
• [39]Mentink-Kane MM, Wynn TA: Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. Immunol Rev 2004, 202:191-202.
• [40]Daley E, Emson C, Guignabert C, de Wall MR, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, Grunig E, Grunig G: Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 2008, 205:361-372.
• [41]Hecker M, Zastona Z, Kwapiszewska G, Niess G, Zakrzewicz A, Hergenreider E, Wilhelm J, Marsh LM, Sedding D, Klepetko W, Lohmeyer J, Dimmeler S, Seeger W, Weismann N, Schermuly RT, Kneidinger N, Eickelberg O, Morty RE: Dysregulation of the IL-13 receptor system. a novel pathomechanism in pulmonary arterial hypertension. Am J Resp Crit Care Med 2010, 182:805-818.
• [42]Crosby A, Jones FM, Kolosionek E, Southwood M, Purvis I, Soon E, Butrous G, Dunne DE, Morrell NW: Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis. Am J Resp Crit Care Med 2011, 184(4):467-473.
• [43]Andrade ZA: Regression of hepatic fibrosis. Rev Soc Bras Med Trop 2005, 38(6):514-520.
• [44]Ruiz-Guevara R, Noya BA, Valero SK, Lecuna P, Garassini M, Noya O: Clinical and ultrasound findings before and after praziquantel treatment among Venezuelan schistosomotic patients. Rev Soc Bras Med Trop 2007, 40(5):505-511.